FindTrial
Sign In

NEFECON

DRUG5 trials

Sponsors

Calliditas Therapeutics AB, Everest Medicines (Singapore) Pte. Ltd., Chinese PLA General Hospital, Nanfang Hospital, Southern Medical University

Conditions

IgA GlomerulonephritisIgA Nephropathy (IgAN)Primary IgA NephropathyPrimary Immunoglobulin a Nephropathy (IgAN)

Phase 2

The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
CompletedNCT01738035
Calliditas Therapeutics ABPrimary IgA Nephropathy
Start: 2012-12-31End: 2015-09-30Updated: 2015-09-24

Phase 3

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
CompletedNCT03643965
Calliditas Therapeutics ABPrimary IgA Nephropathy
Start: 2018-09-05End: 2023-07-10Updated: 2024-12-03
Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
CompletedNCT05534919
Everest Medicines (Singapore) Pte. Ltd.Primary Immunoglobulin a Nephropathy (IgAN)
Start: 2022-12-09End: 2024-07-17Updated: 2024-11-12

Phase 4

Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
RecruitingNCT07604311
Nanfang Hospital, Southern Medical UniversityIgA Nephropathy (IgAN)
Start: 2026-06-23End: 2028-12-31Target: 288Updated: 2026-09-02

Unknown Phase

Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
RecruitingNCT07585981
Chinese PLA General HospitalIgA Glomerulonephritis
Start: 2025-10-20End: 2027-10-01Target: 30Updated: 2026-05-14

Related Papers

Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan.
2025-11-20
#2642 Effects of Nefecon on hits 1, 2, and 3 of the pathogenic cascade of IgA nephropathy: a full NefIgArd analysis
Nephrology Dialysis Transplantation2025-10-01
Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.
2025-06-101 citations
Ovid Embase search string.
OPAL (Open@LaTrobe) (La Trobe University)2025-06-10
PubMed search string.
OPAL (Open@LaTrobe) (La Trobe University)2025-06-10
Risk of bias assessment for all included RCTs.
OPAL (Open@LaTrobe) (La Trobe University)2025-06-10
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results
Kidney3602024-10-097 citations
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
2023-08-14154 citations
#4049 NEFECON® TREATMENT LIKELY MODULATES DOWNSTREAM PATHWAYS OF KIDNEY INFLAMMATION AND FIBROSIS IN IGA NEPHROPATHY
Nephrology Dialysis Transplantation2023-06-012 citations
Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States.
2023-03-296 citations
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
2023-03-0420 citations
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
2023-02-0940 citations
Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review.
2023-01-0416 citations
Kann man die IgA-Nephritis im Darm behandeln?
Kompass Autoimmun2023-01-01
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
2022-10-19164 citations
Intestinal permeability in patients with IgA nephropathy and other glomerular diseases: an observational study
Journal of Nephrology2022-09-1512 citations
FC050: Nefecon® Selectively Modifies the Composition of Circulating Immune Complexes in IGA Nephropathy
Nephrology Dialysis Transplantation2022-05-013 citations
FC049: Nefecon® (Budesonide) is an Epigenetic Modifier in IGA Nephropathy
Nephrology Dialysis Transplantation2022-05-013 citations
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
Nephrology Dialysis Transplantation2020-08-10180 citations
P0344NEFECON® (BUDESONIDE) SELECTIVELY REDUCES CIRCULATING LEVELS OF BAFF (BLYS) AND SOLUBLE BCMA AND TACI IN IGA NEPHROPATHY
Nephrology Dialysis Transplantation2020-06-016 citations

3 more papers not shown